← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Toripalimab)

Paget Disease, Extramammary; Scrotum Disease · Paget Disease, Extramammary

#PagetDiseaseExtramammary#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
임상시험 17상태 RECRUITING
ADCBiologicstaleGenentech, Inc.Phase 1

GDC-0941 (GDC-0941)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 17상태 ACTIVE
ADCBiologicstaleShanghai Henlius BiotechPhase 2

HLX43 (HLX43)

Advanced/Metastatic Malignant Solid Tumors · Hormone Receptor Positive HER-2 Negative

#HormoneReceptorPositiveHER-2Nega#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleShanghai JMT-Bio Inc.Phase 2

KN026 (KN026)

HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleEli Lilly and CompanyPhase 3

MIRV (MIRV)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 51.9%임상시험 17상태 RECRUITING
AntibodystaleAmgenPhase 2

Panitumumab + paclitaxel (Panitumumab + paclitaxel)

Head and Neck Cancer · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Phase2#항체#면역항체+2
효능 ORR 77.3%임상시험 17상태 ACTIVE
ADCBiologicstaleSuzhou Suncadia Biopharmaceutic…Phase 2

SHR-A1921 (SHR-A1921)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 1%임상시험 17상태 RECRUITING
AntibodystaleKite, A Gilead CompanyPhase 1

Utomilumab (Utomilumab)

Relapsed/Refractory Large B-cell Lymphoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
효능 ORR 67%임상시험 17상태 ACTIVE
ADCBiologicstaleBeiGenePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, tislelizumab+disitamab-vedotin)

Neoadjuvant Immunotherapy · Neoadjuvant Immunotherapy

#NeoadjuvantImmunotherapy#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
임상시험 17상태 RECRUITING
AntibodystaleRochePhase 3

zanubrutinib, rituximab and lenalidomide (zanubrutinib, rituximab and lenalidomide)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+2
효능 ORR 45.7%임상시험 17상태 RECRUITING
AntibodystaleRochePhase 2

90Yttrium-Ibritumomab Tiuxetan (Zevalin®, 90Yttrium-Ibritumomab Tiuxetan, 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab)

Follicular Lymphoma · Follicular Lymphoma

#FollicularLymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 89%임상시험 16상태 ACTIVE
CGTBiologicstaleStephan Grupp MD PhDPhase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 16상태 RECRUITING
AntibodystaleAkesoPhase 2

Ivonescimab（AK112，a PD-1/VEGF bispecific antibody） (Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）)

Bladder Cancer; Muscle-invasive Bladder Cancer · PD-1

#PD-1#Antibody#Phase2#항체#면역항체+4
임상시험 16상태 RECRUITING
CGTBiologicstaleDutch Cancer SocietyPhase 1

UCB-NK cells (UCB-NK cells)

Recurrent Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma

#RecurrentOvarianCarcinoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 16상태 ACTIVE
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 1

ALX148 (ALX148)

HER2-positive Breast Cancer; Metastatic Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 15상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (AZD5305)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
CGTBiologicPaolo Caimi, MDPhase 1

BAFF CAR-T (BAFF CAR-T)

Relapsed CLL; Refractory CLL · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 15상태 RECRUITING
CGTBiologicLiping DouPhase 2

CD22/CD19 Dual-Target CAR-T Cells (CD22/CD19 Dual-Target CAR-T Cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 15상태 RECRUITING
AntibodystaleSanofiApproved

Dupilumab Prefilled Syringe (Dupilumab Prefilled Syringe)

Netherton Syndrome · Netherton Syndrome

#NethertonSyndrome#Antibody#Approved#항체#면역항체+2
임상시험 15상태 RECRUITING

42 / 209 페이지

← 이전다음 →